NASDAQ: ZBIO
Zenas Biopharma Inc Stock

$7.27-0.30 (-3.96%)
Updated Feb 11, 2025
ZBIO Price
$7.27
Fair Value Price
N/A
Market Cap
$303.82M
52 Week Low
$5.83
52 Week High
$26.25
P/E
N/A
P/B
0.85x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.12
Operating Cash Flow
N/A
Beta
1.52
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ZBIO Overview

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ZBIO's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

C
Value
C
Growth
C
Momentum
C
Sentiment
C
Safety
D
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
ZBIO
Ranked
#356 of 558

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important ZBIO news, forecast changes, insider trades & much more!

Overview

Due Diligence Score

–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ZBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ZBIO is good value based on its book value relative to its share price (0.85x), compared to the US Biotechnology industry average (4.8x)
P/B vs Industry Valuation
ZBIO's short-term assets ($393.78M) exceed its short-term liabilities ($44.00M)
Short-term Liabilities Financials
ZBIO's short-term assets ($393.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more ZBIO due diligence checks available for Premium users.

Valuation

ZBIO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.85x
Industry
4.8x
ZBIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ZBIO's financial health

Profit margin

Revenue
$0.0
Net Income
-$38.6M
Profit Margin
0%

Assets to liabilities

Assets
$403.4M
Liabilities
$44.0M
Debt to equity
0.12
ZBIO's short-term assets ($393.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ZBIO's short-term assets ($393.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ZBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$31.1M
Investing
-$26.8M
Financing
$234.0M

ZBIO vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ZBIOD$303.82M-3.96%N/A0.85x
TRVID$304.39M-2.46%-9.00x5.16x
OLMAD$299.09M+1.16%-2.39x1.50x
PRMEC$299.05M-5.79%-1.11x1.58x
FHTXC$298.54M+1.51%-2.80x-10.55x

Zenas Biopharma Stock FAQ

What is Zenas Biopharma's quote symbol?

(NASDAQ: ZBIO) Zenas Biopharma trades on the NASDAQ under the ticker symbol ZBIO. Zenas Biopharma stock quotes can also be displayed as NASDAQ: ZBIO.

If you're new to stock investing, here's how to buy Zenas Biopharma stock.

What is the 52 week high and low for Zenas Biopharma (NASDAQ: ZBIO)?

(NASDAQ: ZBIO) Zenas Biopharma's 52-week high was $26.25, and its 52-week low was $5.83. It is currently -72.31% from its 52-week high and 24.7% from its 52-week low.

How much is Zenas Biopharma's stock price per share?

(NASDAQ: ZBIO) Zenas Biopharma stock price per share is $7.27 today (as of Feb 11, 2025).

What is Zenas Biopharma's Market Cap?

(NASDAQ: ZBIO) Zenas Biopharma's market cap is $303.82M, as of Feb 12, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Zenas Biopharma's market cap is calculated by multiplying ZBIO's current stock price of $7.27 by ZBIO's total outstanding shares of 41,791,037.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.